Investment
Co-led CORE Biomedicine's $21M Series A financing alongside UTokyo Innovation Platform to advance precision oncology programs.
CORE Biomedicine
JUL 28, 2026
Every public signal F4 has attached to this firm, with sources and cross-entity links.
CORE Biomedicine
Agibot Medical Technology
Ucello Therapeutics